Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
By B. Nordlinger, H. Sørbye, B. Glimelius, G. Poston, P. Schlag, P. Rougier, W. Bechstein, J. Primrose, E. Walpole, M. Finch-Jones and 8 more. The Lancet Oncology, 2013
1,113 citations recorded by the source corpus.
Subfields: Hepatology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/8b7dadef5830fa815dbb4a183d0b949661a47d57
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Oncology
Citations in the corpus
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017, background): “This number approximates the 40% eight-year overall survival in the recently published Eloxatin Peri-Operative Chemotherapy (EPOC) study, in which patients with one to four resectable colorectal liver metastases (median number of lesions 1⁄4 1) were treated by resection plus systemic treatment (28).”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “However, the only phase III trial in this situation has shown a benefit in disease-free survival and non-significant improvement of OS (51% at 5 years) if perioperative treatment with FOLFOX is administered [I, B] [52, 53].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “The preferred treatment in this setting should be FOLFOX [or alternatively capecitabine with oxaliplatin (CAPOX)] as reported for the EPOC trial [163, 164].”